Recent studies offer new insights into ALK detection methods and related treatments. Screening for the non-small cell lung cancer (NSCLC) subtype has been at the forefront of NSCLC research, and ...
Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation Patients age ≥ 18 years with two or more visits ...
Wiesbaden, Germany - Abbott (NYSE: ABT) today announced the availability of a new molecular test in the European Union and New Zealand designed to identify the presence of gene rearrangements ...
A novel technique for detecting ALK rearrangements in non-small cell lung cancers (NSCLCs) has been developed that is more sensitive and easier to perform than currently available techniques. The ...
ABBOTT PARK, Ill., Oct. 24, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will expand the current CE-IVD product labeling for its Vysis ® ALK Break Apart FISH Probe Kit, allowing the ...
Simultaneous Approval of New Treatment and Companion Diagnostic Represents Significant Advance in Personalized Medicine for Patients with Non-Small-Cell Lung Cancer ABBOTT PARK, Ill., Aug. 26, 2011 ...
LOS ANGELES--(BUSINESS WIRE)--Response Genetics Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ...
Routine testing with both fluorescent in situ hybridization and immunohistochemistry may enhance the detection of ALK-positive non-small cell lung cancer, new research suggests. Accurate determination ...
Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation Patients age ≥ 18 years with two or more visits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback